Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Apyx Medical's accounts receivables for the quarter that ended in Jun. 2026 was $13.61 Mil.
Accounts receivable can be measured by Days Sales Outstanding.
Apyx Medical's Days Sales Outstanding for the quarter that ended in Jun. 2026 was 89.48.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Apyx Medical's Net-Net Working Capital per share for the quarter that ended in Jun. 2026 was $-0.17.
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
Apyx Medical's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Apyx Medical's accounts receivable are only considered to be worth 75% of book value:
Apyx Medical's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
Apyx Medical Accounts Receivable Related Terms
Apyx Medical Accounts Receivable Historical Data
* Premium members only.
The historical data trend for Apyx Medical's Accounts Receivable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Accounts Receivable of $13.61 Mil mean?
Apyx Medical (APYX) has a Accounts Receivable of $13.61 Mil as of Jun. 2026. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Apyx Medical and its competitors.
Is Apyx Medical's Accounts Receivable too high?
Apyx Medical's current Accounts Receivable is $13.61 Mil. Overall, Apyx Medical has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Apyx Medical's Accounts Receivable compare to INGN and QSI?
Apyx Medical's Accounts Receivable of $13.61 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Receivable for a Medical Devices & Instruments company?
A good Accounts Receivable depends on the Medical Devices & Instruments industry context. However, Accounts Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Receivable mean?
A high Accounts Receivable can signal that a stock is expensive relative to its fundamentals. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Apyx Medical and its competitors. Apyx Medical's current Accounts Receivable is $13.61 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apyx Medical stock overvalued right now?
Based on GuruFocus' analysis, Apyx Medical (APYX) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.21, compared to a current price of $3.08 — trading 39.4% above its estimated fair value. The current Accounts Receivable is $13.61 Mil. Apyx Medical's overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Receivable calculated?
Accounts Receivable is calculated from a company's financial statements. For Apyx Medical (APYX), the current Accounts Receivable is $13.61 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Apyx Medical (APYX) Overvalued in 2026?
Based on GuruFocus' analysis, Apyx Medical stock appears to be overvalued.
The current stock price of $3.08 is trading 39.4% above its estimated GF Value™ of $2.21.
GuruFocus considers Apyx Medical to be Significantly Overvalued.
Key valuation signals for APYX:
Accounts Receivable: $13.61 Mil
GF Value™: $2.21 vs. price of $3.08 (39.4% above fair value)
No single metric tells the full story. See the APYX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Surgical Aesthetics and Original Equipment Manufacturing (OEM). Its Surgical Aesthetics segment derives the majority of its revenue.
72GF Score
Get the complete analysis for APYX
Accounts Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APYX has been successfully added to your 
